Lonestar Capital Management LLC Prothena Corp Public LTD CO Transaction History

Lonestar Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$11.0 - $28.24 $516,615 - $1.33 Million	-46,965 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $1.71 Million - $2.36 Million	-169,435 Reduced 78.3%	46,965 $564,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $721,116 - $978,191	-72,620 Reduced 25.13%	216,400 $2.16 Million
Q2 2020 Aug 12, 2020	SELL	$9.56 - $12.51 $487,426 - $637,834	-50,986 Reduced 15.0%	289,020 $3.02 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $301,645 - $630,894	40,006 Added 13.34%	340,006 $3.64 Million
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $2.07 Million - $3.14 Million	300,000 New	300,000 $2.35 Million

179

42.8M

77.7K

92.7K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $798M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Lonestar Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lonestar Capital Management LLC with notifications on news.